Praxis Precision Medicines Inc.
Praxis Precision Medicines Reports Third Quarter 2025 Financial Results and Operational Highlights
Summary
Praxis Precision Medicines, Inc. reported its third-quarter 2025 financial results and provided a corporate update on November 5, 2025. The company announced positive results from two pivotal Phase 3 Essential3 studies of ulixacaltamide in essential tremor, plans to accelerate the development of relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies, and recruitment completion for the POWER1 study of vormatrigine in focal onset seizures. The company also disclosed financial results, showing a net loss of $73.9 million for the quarter, driven by increased research and development expenses. Cash, cash equivalents, and marketable securities as of September 30, 2025, are approximately $389.2 million, and with proceeds from an October 2025 public offering, Praxis is well-funded into 2028.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement